[go: up one dir, main page]

JPS56110612A - Readily disintegrable and absorbable compression molded article of slightly soluble drug - Google Patents

Readily disintegrable and absorbable compression molded article of slightly soluble drug

Info

Publication number
JPS56110612A
JPS56110612A JP1441380A JP1441380A JPS56110612A JP S56110612 A JPS56110612 A JP S56110612A JP 1441380 A JP1441380 A JP 1441380A JP 1441380 A JP1441380 A JP 1441380A JP S56110612 A JPS56110612 A JP S56110612A
Authority
JP
Japan
Prior art keywords
slightly soluble
soluble drug
polyethylene glycol
molded article
compression molded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1441380A
Other languages
Japanese (ja)
Inventor
Katsuhiko Yano
Tadayoshi Omura
Masayoshi Ariga
Hiromitsu Kawada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Priority to JP1441380A priority Critical patent/JPS56110612A/en
Publication of JPS56110612A publication Critical patent/JPS56110612A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

PURPOSE: A compression molded article having improved disintegrating property and absorbability of a slightly soluble drug, and prepared by incorporating the slightly soluble drug with polyvinyl pyrrolidone, etc. alone or further polyethylene glycol, etc., and granulating the resultant mixture by the fluidized bed granulating method.
CONSTITUTION: A slightly soluble drug, e.g. nifedipine, is incorporated with (A) polyvinyl pyrrolidone, methyl cellulose, hydroxypropyl (methyl) cellulose or/and solid polyethylene glycol or (B) the first component consisting of the respective compounds in (A) except the solid polyethylene glycol, urea, citric acid, mannitol, succinic acid or/and amino acid and the second component consisting of a surfactant, polyethylene glycol, propylene glycol, glycerol, glycerol ester of a fatty acid or/and a vegetable oil. The resultant mixture is then granulated by the well-known fluidized bed granulating method.
COPYRIGHT: (C)1981,JPO&Japio
JP1441380A 1980-02-08 1980-02-08 Readily disintegrable and absorbable compression molded article of slightly soluble drug Pending JPS56110612A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP1441380A JPS56110612A (en) 1980-02-08 1980-02-08 Readily disintegrable and absorbable compression molded article of slightly soluble drug

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1441380A JPS56110612A (en) 1980-02-08 1980-02-08 Readily disintegrable and absorbable compression molded article of slightly soluble drug

Publications (1)

Publication Number Publication Date
JPS56110612A true JPS56110612A (en) 1981-09-01

Family

ID=11860344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1441380A Pending JPS56110612A (en) 1980-02-08 1980-02-08 Readily disintegrable and absorbable compression molded article of slightly soluble drug

Country Status (1)

Country Link
JP (1) JPS56110612A (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002056A1 (en) * 1981-12-18 1983-06-23 Key Pharma Expandable lattice of polyvinyl alcohol and polyethylene glycol
WO1984000296A1 (en) * 1982-07-09 1984-02-02 Key Pharma Quinidine sustained release dosage formulation
US4562069A (en) * 1983-05-21 1985-12-31 Bayer Aktiengesellschaft Two-phase formulation
JPS6168431A (en) * 1984-09-11 1986-04-08 バイエル・アクチエンゲゼルシヤフト Solid medicine containing nitrendipine and manufacture
JPH01299226A (en) * 1988-05-27 1989-12-04 Seikagaku Kogyo Co Ltd Enteric granule of salazosulfapyridine
JPH04210919A (en) * 1990-01-20 1992-08-03 Dr Karl Thomae Gmbh Pimobendan oral formulation
WO1998029137A1 (en) * 1996-12-25 1998-07-09 Yamanouchi Pharmaceutical Co., Ltd. Immediately disintegrable medicinal compositions
US6144280A (en) * 1996-11-29 2000-11-07 Taiyo Yuden Co., Ltd. Wire wound electronic component and method of manufacturing the same
JP2003513904A (en) * 1999-11-12 2003-04-15 アボット・ラボラトリーズ Crystallization inhibitors in solid dispersants
US7125565B2 (en) 2000-12-01 2006-10-24 Kyowa Hakko Kogyo Co., Ltd. Composition improved in the solubility or oral absorbability
JP2006335767A (en) * 1999-09-17 2006-12-14 Novartis Ag Methods for treating metabolic disorders, especially diabetes, or diabetes-related diseases or conditions
WO2007138997A1 (en) * 2006-05-26 2007-12-06 Toyama Chemical Co., Ltd. Oral composition comprising 3-[5-[4-(cyclopentyloxy) -2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6- yl)methoxy]phenyl]propionic acid or salt thereof
JP2009522278A (en) * 2005-12-28 2009-06-11 バーテックス ファーマシューティカルズ インコーポレイテッド Solid form of N- [2,4-bis (1,1-dimethylethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
JP2011136922A (en) * 2009-12-28 2011-07-14 Lion Corp Ibuprofen-containing pharmaceutical preparation
JP4875277B2 (en) * 2000-06-16 2012-02-15 田辺三菱製薬株式会社 Release pH range and / or rate controlling composition
KR20120073111A (en) 2010-12-24 2012-07-04 라이온 가부시키가이샤 refine
JP2013028636A (en) * 2000-10-24 2013-02-07 Ajinomoto Co Inc Nateglinide-containing preparation
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2019169793A1 (en) * 2018-03-07 2019-09-12 深圳市伯劳特生物制品有限公司 Composition, chip and preparation method for chip and detection device including chip
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10662192B2 (en) 2004-06-24 2020-05-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2400819A1 (en) * 1974-01-09 1975-07-17 Bayer Ag PROCESS FOR MANUFACTURING SOLID PREPARATIONS OF DIFFICULT MEDICINAL ACTIVE SUBSTANCES IN FINE DISTRIBUTION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2400819A1 (en) * 1974-01-09 1975-07-17 Bayer Ag PROCESS FOR MANUFACTURING SOLID PREPARATIONS OF DIFFICULT MEDICINAL ACTIVE SUBSTANCES IN FINE DISTRIBUTION

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002056A1 (en) * 1981-12-18 1983-06-23 Key Pharma Expandable lattice of polyvinyl alcohol and polyethylene glycol
WO1984000296A1 (en) * 1982-07-09 1984-02-02 Key Pharma Quinidine sustained release dosage formulation
US4432965A (en) * 1982-07-09 1984-02-21 Key Pharmaceuticals, Inc. Quinidine sustained release dosage formulation
US4562069A (en) * 1983-05-21 1985-12-31 Bayer Aktiengesellschaft Two-phase formulation
JPS6168431A (en) * 1984-09-11 1986-04-08 バイエル・アクチエンゲゼルシヤフト Solid medicine containing nitrendipine and manufacture
JPH01299226A (en) * 1988-05-27 1989-12-04 Seikagaku Kogyo Co Ltd Enteric granule of salazosulfapyridine
JPH04210919A (en) * 1990-01-20 1992-08-03 Dr Karl Thomae Gmbh Pimobendan oral formulation
US6144280A (en) * 1996-11-29 2000-11-07 Taiyo Yuden Co., Ltd. Wire wound electronic component and method of manufacturing the same
US6449830B1 (en) 1996-11-29 2002-09-17 Taiyo Yuden Co., Ltd. Method of manufacturing wire wound electronic component
US6727792B2 (en) 1996-11-29 2004-04-27 Taiyo Yuden Co., Ltd. Method of manufacturing wire wound electronic component
WO1998029137A1 (en) * 1996-12-25 1998-07-09 Yamanouchi Pharmaceutical Co., Ltd. Immediately disintegrable medicinal compositions
US7189415B2 (en) 1996-12-25 2007-03-13 Astellas Pharma Inc. Rapidly disintegrable pharmaceutical composition
US6899899B2 (en) 1996-12-25 2005-05-31 Yamanouchi Pharmaceutical Co., Ltd. Rapidly disintegrable pharmaceutical composition
JP2006335767A (en) * 1999-09-17 2006-12-14 Novartis Ag Methods for treating metabolic disorders, especially diabetes, or diabetes-related diseases or conditions
JP2003513904A (en) * 1999-11-12 2003-04-15 アボット・ラボラトリーズ Crystallization inhibitors in solid dispersants
JP2013224297A (en) * 1999-11-12 2013-10-31 Abbott Lab Inhibitor of crystallization in solid dispersion
US8883777B2 (en) 2000-06-16 2014-11-11 Mitsubishi Tanabe Pharma Corporation Compositions controlling pH range of release and/or release rate
JP4875277B2 (en) * 2000-06-16 2012-02-15 田辺三菱製薬株式会社 Release pH range and / or rate controlling composition
JP2013028636A (en) * 2000-10-24 2013-02-07 Ajinomoto Co Inc Nateglinide-containing preparation
US7799860B2 (en) 2000-12-01 2010-09-21 Kyowa Hakko Kirin Co., Ltd. Composition improved in the solubility or oral absorbability
US7125565B2 (en) 2000-12-01 2006-10-24 Kyowa Hakko Kogyo Co., Ltd. Composition improved in the solubility or oral absorbability
US10662192B2 (en) 2004-06-24 2020-05-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP2009522278A (en) * 2005-12-28 2009-06-11 バーテックス ファーマシューティカルズ インコーポレイテッド Solid form of N- [2,4-bis (1,1-dimethylethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
US10537565B2 (en) 2005-12-28 2020-01-21 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9931334B2 (en) 2005-12-28 2018-04-03 Vertex Pharmaceuticals Incorporated Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US11291662B2 (en) 2005-12-28 2022-04-05 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP2014012701A (en) * 2005-12-28 2014-01-23 Vertex Pharmaceuticals Inc Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP2015096539A (en) * 2005-12-28 2015-05-21 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8093289B2 (en) 2006-05-26 2012-01-10 Toyama Chemical Co., Ltd. Oral composition comprising 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionic acid or salt thereof
JP5161077B2 (en) * 2006-05-26 2013-03-13 富山化学工業株式会社 Contains 3- {5- [4- (cyclopentyloxy) -2-hydroxybenzoyl] -2-[(3-hydroxy-1,2-benzisoxazol-6-yl) methoxy] phenyl} propionic acid or a salt thereof Oral composition
WO2007138997A1 (en) * 2006-05-26 2007-12-06 Toyama Chemical Co., Ltd. Oral composition comprising 3-[5-[4-(cyclopentyloxy) -2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6- yl)methoxy]phenyl]propionic acid or salt thereof
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11564916B2 (en) 2008-08-13 2023-01-31 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
JP2011136922A (en) * 2009-12-28 2011-07-14 Lion Corp Ibuprofen-containing pharmaceutical preparation
KR20120073111A (en) 2010-12-24 2012-07-04 라이온 가부시키가이샤 refine
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11147770B2 (en) 2012-02-27 2021-10-19 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11752106B2 (en) 2012-02-27 2023-09-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US12214083B2 (en) 2012-02-27 2025-02-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2019169793A1 (en) * 2018-03-07 2019-09-12 深圳市伯劳特生物制品有限公司 Composition, chip and preparation method for chip and detection device including chip

Similar Documents

Publication Publication Date Title
JPS56110612A (en) Readily disintegrable and absorbable compression molded article of slightly soluble drug
ZA889441B (en) Pharmaceutical compositions
HK40583A (en) Nifedipine-containing solid preparation composition
CA2066248A1 (en) Esters of thienyl carboxylic acids and amino alcohols, their quaternization products, and manufacture and use of said compounds
ATE147261T1 (en) METHOD FOR PRODUCING HIGH STRENGTH TABLETS
CA2376202A1 (en) Novel preparation and administration form comprising an acid-labile active compound
HUT49629A (en) Process for producing peptide-boronic acid derivatives inhibiting trypsin-like proteases and pharmaceutical compositions comprising such compounds as active ingredient
HUT57541A (en) Fungicidal compositions comprising substituted acrylic acid esters as active ingredient and process for producing the active ingredients
HUT59106A (en) Process for producing 3-amidopyrazoles and pharmaceutical compositions comprising such compounds as active ingredient
ATE87824T1 (en) DELAYED-RELEASE PRODUCTS.
HUT50794A (en) Herbicides comprising substituted benztriazole derivatives as active ingredient and process for producing the active ingredients
HUT61031A (en) Process for producing chemically modified, stable haemoglobin substituting for non-immunogehic red blood cell, and pharmaceutical compositions comprising same as active ingredient
CA2245708A1 (en) Solid formulations containing trehalose
EP0461630A3 (en) Production process of microspheres
HUT61298A (en) Process for producing bicyclic heterocyclic compounds and pharmaceutical composition comprising same as active ingredient
FR2601259B1 (en) NOVEL SURFACTANT COMPOSITIONS BASED ON PHOSPHORIC ESTERS, THEIR PREPARATION PROCESS AND THEIR APPLICATION TO THE FORMULATION OF ACTIVE MATERIALS.
HUT52078A (en) Herebicidal compositions comprising thiazole derivatives as active ingredient and process for producing the active ingredients
TWI255720B (en) Novel preparation and administration form comprising an acid-labile active compound and process for production thereof
AU692801B2 (en) Pharmaceutical compositions comprising a staurosporine as active ingredient.
HUT66238A (en) Bicyclic carboxylic acid derivatives, pharmaceutical compositions contg. them as active agent and process to prepare them
HUT50334A (en) Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient
AU4480889A (en) A pharmaceutical composition for rapid release of the active component comprising an orderred mixture and a surfactant
DE4124409B4 (en) Pharmaceutical preparations
HUT61024A (en) Process for producing 10(1-hydroxyethyl)-11-oxo-1-aza-tricyclo/7.2.0.0.3.8/undex-2-ene-2-carboxylic acid esters and pharmaceutical compositions comprising same as active ingredient
JPS5649314A (en) Lasting pharmaceutical composition having prolonged action and its preparation